Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$11.06 USD
+0.08 (0.68%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.07 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Zentalis Pharmaceuticals, Inc. [ZNTL]
Reports for Purchase
Showing records 1 - 20 ( 69 total )
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertib is Primed for an Assault on Gynecologic Malignancies in 2024: Reit. Buy and $46 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Were Not Quite There, But the Cupboard Is Far from Bare
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ZNTL 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Downgrading to NEUTRAL as Strategy Shifts for Azeno
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertibs Positive Development Updates Cut Both Ways
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertib Furthers its Positioning Across Oncology; Reit. Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Azenosertib RP2D Dosing Identified, Onto Ph 3 Combo Study Next
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Now Two Steps Forward; Azeno Dose Optimization Pays Off
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Simply the Best: Topline Azeno Combo Data Impresses
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Azenosertib Breaks Ground in PROC Guided by Chemo Synergies and Cyclin E1 Biomarker
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Cyclin E1 Translational Data a Key Focus at ASCO; Reit. Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Key Decisions and Key Data Coming Up
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Rich Catalyst Calendar For Azenosertib (ZN-c3), Holds More Value Than Apparent; Reit Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A